STOCK TITAN

ParkerVision (PRKR) registers 5.87M shares for resale; director change noted

(Neutral)
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

ParkerVision, Inc. registers 5,871,584 shares of Common Stock for resale by selling stockholders under a Prospectus Supplement dated May 21, 2026. The company will not receive proceeds from these resales. The supplement attaches a Form 8-K filed May 21, 2026, which furnishes a press release.

The Form 8-K discloses a director resignation and board appointment: May 15, 2026 resignation of Lewis Titterton (retirement) and appointment of Anthony Bowers on May 19, 2026, who joins the Audit and Compensation Committees and will receive standard non-employee director compensation and the company’s standard indemnification agreement.

Positive

  • None.

Negative

  • None.

Insights

Board turnover is routine and disclosed with basic director background.

The filing states a director resignation due to retirement on May 15, 2026 and the board’s unanimous appointment of Anthony Bowers on May 19, 2026. The filing notes committee assignments and standard non-employee director compensation and an indemnification agreement.

Dependencies include the board’s ongoing committee oversight and any future disclosures regarding committee leadership or related-party transactions; subsequent filings would show such details if they arise.

This is a resale registration; it does not raise capital for the issuer.

The Prospectus Supplement registers 5,871,584 shares for resale by selling stockholders and expressly states the company will not receive proceeds from those sales. The supplement incorporates a Form 8-K as an update.

Cash-flow treatment is explicit: proceeds go to selling holders. Market impact depends on holder selling decisions and timing, which are not disclosed in this excerpt.

Registered shares 5,871,584 shares Prospectus Supplement dated <date>May 21, 2026</date>
Prospectus supplement date <date>May 21, 2026</date> Date of this Prospectus Supplement
Director resignation date <date>May 15, 2026</date> Lewis Titterton resignation
Director appointment date <date>May 19, 2026</date> Anthony Bowers appointment
New director age 69 years Anthony Bowers age as disclosed
Prospectus Supplement regulatory
"This Prospectus Supplement relates to the prospectus dated September 2, 2020"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
selling stockholders financial
"resale by the selling stockholders listed in the Prospectus of up to 5,871,584 shares"
Selling stockholders are existing owners of a company's shares who are offering some or all of their holdings for sale, often as part of a public offering or secondary transaction. For investors this matters because such sales increase the number of shares available to buy, can signal how confident current owners are about future prospects, and may put short-term pressure on the stock price similar to more tickets being released for a popular event.
Form 8-K regulatory
"update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
indemnification agreement legal
"The Company entered into its standard indemnification agreement with Mr. Bowers"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Offering Type resale/secondary
Use of Proceeds issuer will not receive proceeds from the resale

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does the ParkerVision (PRKR) prospectus supplement register?

The supplement registers 5,871,584 shares of Common Stock for resale by selling stockholders. The filing updates the prior prospectus and attaches a Form 8-K dated May 21, 2026 with an accompanying press release.

Will ParkerVision receive proceeds from the registered resale (PRKR)?

No. The supplement states the company will not receive proceeds from sales by the selling stockholders. The registered shares are being offered for resale by holders who originally received the shares under purchase agreements in 2020.

What board changes does the attached Form 8-K disclose for PRKR?

The Form 8-K discloses the resignation of Lewis Titterton due to retirement on May 15, 2026 and the appointment of Anthony Bowers on May 19, 2026, who was added to the Audit and Compensation Committees and will receive standard director compensation.

How many shares were originally issued that are now registered for resale?

The prospectus supplement identifies an aggregate of 5,871,584 shares of Common Stock issued under securities purchase agreements dated in 2020. These same shares are the subject of the resale registration in this supplement.

Filed pursuant to Rule 424(b)(3)

Registration No. 333-248242

 

PROSPECTUS SUPPLEMENT No. 68

(to Prospectus dated September 2, 2020)

 

PARKERVISION, INC.

5,871,584 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated September 2, 2020, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 5,871,584 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of an aggregate of 5,871,584 shares of Common Stock issued pursuant to securities purchase agreements dated April 29, 2020, May 22, 2020, June 8, 2020, June 29, 2020, July 24, 2020, and August 19, 2020.

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 21, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement.

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.”

 

You should read this prospectus and any prospectus supplement carefully before you invest in any of our securities.

 

Investing in our securities involves a high degree of risk. See Risk Factors beginning on page 5 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined whether this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is May 21, 2026.

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 15, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 15, 2026, Mr. Lewis Titterton resigned from the Board of Directors (the “Board”) of ParkerVision, Inc. (the "Company"), and from the Audit and Compensation Committees on which he served.  Mr. Titterton’s resignation was due to retirement and not due to any disagreement with the Company or any matter relating to the Company's operations, policies or practices. 

 

On May 19, 2026, the Board unanimously appointed Anthony Bowers to fill the director vacancy created by Mr. Titterton’s resignation.  Mr. Bowers was also appointed to the Audit and Compensation Committees of the Board.

 

Mr. Bowers, age 69, has served as Director of Corporate Sales at Intro-act, LLC since 2017.  Prior to joining Intro-act, LLC, Mr. Bowers held positions in corporate and institutional sales, including leadership roles at OTR Global and Goldman Sachs.  Mr. Bowers holds an MBA in Accounting and Finance from the Wharton School and a bachelor's degree in economics from Amherst College. 

 

There are no arrangements or understandings between Mr. Bowers and any other persons pursuant to which he was selected as a director.  There are no transactions involving Mr. Bowers requiring disclosure under Item 404(a) of Regulation S-K.

 

Mr. Bowers will receive the Company's standard non-employee director compensation arrangements.  The Company entered into its standard indemnification agreement with Mr. Bowers.

 

The Company issued a press release announcing the resignation of Mr. Titterton and the appointment of Mr. Bowers, a copy of which is furnished herewith as Exhibit 99.1.

 

 

 Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit

Description

99.1 Press Release dated May 21, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: May 21, 2026

   
   

PARKERVISION, INC.

     
   

By /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer